Gabelli Funds LLC Has $3.22 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Gabelli Funds LLC decreased its position in NeoGenomics, Inc. (NASDAQ:NEO) by 9.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,760 shares of the medical research company’s stock after selling 5,940 shares during the quarter. Gabelli Funds LLC owned about 0.05% of NeoGenomics worth $3,217,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of NeoGenomics by 5.3% in the 4th quarter. BlackRock Inc. now owns 17,246,570 shares of the medical research company’s stock valued at $928,557,000 after acquiring an additional 861,490 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its position in NeoGenomics by 747.6% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 296,528 shares of the medical research company’s stock valued at $15,966,000 after acquiring an additional 261,545 shares in the last quarter. Perkins Capital Management Inc. bought a new position in NeoGenomics in the 3rd quarter valued at about $7,360,000. Cubist Systematic Strategies LLC bought a new position in NeoGenomics in the 3rd quarter valued at about $2,774,000. Finally, Voloridge Investment Management LLC lifted its position in shares of NeoGenomics by 572.1% during the 3rd quarter. Voloridge Investment Management LLC now owns 82,891 shares of the medical research company’s stock worth $3,058,000 after buying an additional 70,557 shares in the last quarter. Institutional investors and hedge funds own 91.06% of the company’s stock.
In other news, VP Jennifer Balliet sold 15,000 shares of the company’s stock in a transaction on Friday, December 11th. The shares were sold at an average price of $49.99, for a total transaction of $749,850.00. Following the completion of the sale, the vice president now owns 39,980 shares of the company’s stock, valued at $1,998,600.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Bonello sold 8,000 shares of the company’s stock in a transaction on Wednesday, December 2nd. The stock was sold at an average price of $46.80, for a total transaction of $374,400.00. Following the sale, the insider now directly owns 20,060 shares of the company’s stock, valued at approximately $938,808. The disclosure for this sale can be found here. Insiders have sold 295,809 shares of company stock valued at $14,338,460 over the last 90 days. 6.50% of the stock is currently owned by company insiders.
A number of research analysts recently weighed in on the stock. Craig Hallum lifted their price objective on shares of NeoGenomics from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Benchmark boosted their price target on shares of NeoGenomics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. CIBC upgraded shares of NeoGenomics to an “outperformer” rating and boosted their price target for the company from $10.50 to $14.50 in a research report on Monday, October 26th. Truist initiated coverage on shares of NeoGenomics in a report on Wednesday, January 27th. They issued a “buy” rating and a $65.00 price objective on the stock. Finally, BTIG Research assumed coverage on shares of NeoGenomics in a research note on Friday, December 11th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. NeoGenomics currently has an average rating of “Buy” and a consensus price target of $43.58.
NASDAQ:NEO opened at $56.56 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.22 and a current ratio of 6.54. The company has a fifty day moving average of $54.87 and a two-hundred day moving average of $45.42. The stock has a market capitalization of $6.28 billion, a PE ratio of -1,884.71 and a beta of 0.79. NeoGenomics, Inc. has a fifty-two week low of $20.47 and a fifty-two week high of $61.57.
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Further Reading: Key terms to understand channel trading
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
|CryptoCurrency||USD||Change 1h||Change 24h||Change 7d|
|Bitcoin||1.35 %||2.24 %||5.26 %|
|Ethereum||2.45 %||5.70 %||16.99 %|
|Binance Coin||1.99 %||0.15 %||6.10 %|
|Tether||0.33 %||0.21 %||0.45 %|
|Cardano||0.96 %||1.59 %||13.69 %|
|Polkadot||2.09 %||0.79 %||1.59 %|
|XRP||0.55 %||1.70 %||6.06 %|
|Uniswap||1.37 %||2.60 %||30.38 %|
|Chainlink||0.81 %||4.43 %||20.09 %|
|Litecoin||1.95 %||0.75 %||9.22 %|
|Bitcoin Cash||1.38 %||2.13 %||5.71 %|
|Stellar||1.32 %||1.00 %||2.71 %|
|USD Coin||0.12 %||0.16 %||0.19 %|
|Dogecoin||3.08 %||18.12 %||20.81 %|
|Wrapped Bitcoin||1.32 %||1.98 %||5.13 %|
|NEM||0.76 %||0.42 %||8.87 %|
|Aave||2.90 %||5.00 %||13.47 %|
|Theta Network||1.71 %||13.28 %||50.21 %|
|Cosmos||1.78 %||0.74 %||3.83 %|
|OKB||1.44 %||3.46 %||5.73 %|